Most Favored Nation Drug Pricing Perspectives

US prices for brand-name drugs are substantially higher than in other countries, leading to bipartisan policy concern.
"Most favored nation" (MFN) pricing involves setting US drug prices at the minimum observed price across a set of reference countries.
The objective is "global price compression," which seeks to lower US prices while potentially raising prices in other countries to achieve parity.
James Robinson posits that MFN drug pricing is "an idea whose time has come," though its success depends on defining a "right" value-oriented price for the US.

Reference countries, such as those in the Organization for Economic Cooperation and Development, use HTA to define "fair" drug prices based on quantifying benefits to patients and society.
Key organizations performing these assessments include the United Kingdom National Institute for Health and Care Excellence (NICE) and the Germany Institute for Quality and Efficiency in Health Care (IQWiG).
Relying on international reference pricing effectively "offshores" the foundation for pricing to foreign systems and norms.
Sustained investment in publicly funded US-specific HTA research is suggested to establish durable long-term pricing solutions tailored to domestic costs and social preferences.

Drug companies argue that lower US prices will reduce revenue and sharply cut investments in research and development (R&D).
Models of innovation impact vary: the Congressional Budget Office (CBO) estimated $38$ fewer new drugs over $20$ years, while pharmaceutical industry-funded research on the Inflation Reduction Act suggested more significant reductions.
Policy design, such as Medicare drug price negotiation, may incentivize shifted focus from incremental changes in old drugs toward developing products with high added therapeutic value.
Downward price pressure could also drive large firms to become more efficient stewards of R&D investments without reducing total innovation output.

Verifying increases in net prices outside the US is difficult due to the global opacity of pharmaceutical pricing and the use of rebates and creative accounting.
Major manufacturers, including Johnson & Johnson, have downplayed the impact of MFN deals; Johnson & Johnson noted potential revenue reductions of hundreds of millions against global net revenue of nearly $100 \text{ billion}$ .
In $2023$ , list price cuts of $50 - 80\%$ for insulin products reflected existing concessions to pharmacy benefit managers rather than substantial changes to net company earnings.
Future negotiations may focus on non-price factors like tariffs, tax provisions, and regulatory approval vouchers.

International reference pricing targets the lack of transparency surrounding launch prices in the US, where drugs often debut first.
The author suggests the US should task drug companies with justifying higher domestic prices relative to other countries rather than assuming international prices are too low.
Defining successful policy outcomes requires a clear, value-oriented endpoint determined through comparative effectiveness research and social consensus.